

NINETEENTH ANNUAL REPORT 2011



Abl biotechnologies Limited

ABL Biotechnologies Limited
71, Nehru Nagar Industrial Estate,
2nd Link Street, Kottivakkam,
Chennai – 600 041

Contents**Section I**

Chairman's Message

Section II – Annual Report

Notice
Directors' Report
Report on Corporate Governance
Management Discussions and Analysis Report
Declaration - Code of Conduct
Auditors' certificate on compliance of Corporate Governance
CEO/CFO Certification
Auditors' Report
Annexure to Auditors' report
Financial Statements
 Balance Sheet
 Profit and Loss Account
 Schedules to Balance Sheet
 Schedules to Profit and Loss Account
 Notes on Accounts
 Cash Flow Statement
Balance Sheet Abstract & Company's Profile

Section III

Proxy Form

Board of Directors

Mr. K. O. Isaac - Chairman & Managing Director
Dr. G. Subramanian - Director
Mr. V M Sankaran Nampoothiri – Director

Registered Office

71, Nehru Nagar Industrial Estate,
2nd Link Street, Kottivakkam,
Chennai – 600 041

Research & Development Centre

Falma Laboratories Annexe
No 54-A, Industrial Area
Hoskote
Bangalore- 562114

Auditors

M/s. Pratapkaran Paul & Co.,
Chartered Accountants
New No. 7, Old No.4,
Karpagam Garden,
II Main Road,
Adyar, Chennai - 600 020

Bankers

Axis Bank Limited
Chennai Main Branch
Chennai – 600041

Registrar & Transfer Agent

Cameo Corporate Services Limited
1, Subramaniam Building, Club House
Road,
Off Mount Road,
Chennai – 600 002
Ph.: (044) 28460390 (5 lines)

Chairman's Message

Dear Shareholder,

The last few years have been the most trying for your Company. Its entire business model has had to be reworked thanks to repeated steps by successive governments, who have put greater emphasis on pandering to international business rather than supporting the SME businesses in our segment, in India. Illogical interventions in the form of DPCO proclamations, a myopic Health Ministry, lack of credit support from financial institutions, a downwardly spiralling global economy etc have all added to the extreme difficulties of our business.

On the research side, the premises of technology development and support institutions in the Government have been discarded to the newfound logic of 'a money lending Institution'. Regrettably, the focus of supporting indigenisation of technology and incubating entrepreneurship, has been totally lost, what with placing the objectives of development in the hands of incompetents and being held to ransom by asset managers and lawyers.

It is in this scenario that your Company struggles to find space for its development agenda.

With the re-establishment of the Company's laboratory at Hoskote, near Bangalore, it is hoped that some of the technologies will be revived and developmental issues completed so that these technologies can be out-licensed or sold.

The next year will be critical in this regard. This is therefore the time for all of us to rally around our Company and give it the support that is so essential to its survival.

K.O.Isaac
Chairman

NOTICE
ABL BIOTECHNOLOGIES LTD.
No. 71, Nehru Nagar Industrial Estate,
2nd Link Street ,Kottivakkam, Chennai 600 041

Notice is hereby given that the Nineteenth Annual General Meeting of the Members of the Company will be held on Friday, September 30th, 2011 at 9.30 a.m. at Archana Hall, Asha Nivas, 9, Rutland gate, 5th Street, Nungambakkam, Chennai – 600 041 to transact the following business: -

Ordinary Business:

1. To receive, consider and adopt the audited Balance Sheet as at 31st March 2011, the Profit and Loss Account for the year ended on that date, the Directors' Report and the Auditors' report thereon.
2. To reappoint Mr. V M Sankaran Nampoothiri, Director who retires by rotation and being eligible offers himself for reappointment.
3. To appoint Auditors of the Company and to fix their remuneration. M/s. Pratapkaran Paul & Co., Chartered Accountants, Chennai, the retiring Auditors, are eligible for re-appointment.

**By order of the Board
for Abl Biotechnologies Limited**

**K O Isaac
Managing Director**

Place : Chennai
Date : 05/09/2011

Notes:

1. **A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. PROXY IN ORDER TO BE VALID MUST BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE MEETING.**
2. Shareholders of the Company are requested to approach a depository participant registered with either NSDL or CDSL for dematerialisation of their shares. The ISIN Number of the Company is INE707D01016.
3. Members are requested to notify immediately their change of address, if any, quoting their folio numbers to our Registrars and Share Transfer Agents, Cameo Corporate Services Limited, Subramanian Building, 1, Club House Road, Chennai 600 002.
4. The Register of Members and the Share Transfer Books will remain closed from 26/09/2011 to 30/09/2011 (both days inclusive).

Directors' Report

To
All Members,

Your Directors present the 19th Annual Report, together with the Audited Accounts for the year ended on March 31, 2011.

Financials

During the year under review company did not accept any formulation order and hence have not made any sales. Instead it concentrated in its research activities. Laboratory facilities were shifted and reinstalled in Bangalore. Company recorded a loss of Rs.53 lakhs on account of Development expenses Rs. 8.50 lakhs, write offs Rs. 15.00 lakhs and other overhead expenses of Rs. 30 lakhs.

Operations

Your Company has not done much business during last year but has focused at restructuring itself so as to take advantage of its experience and Intellectual property with a larger focus on commercial applications.

a) R&D Division

The research operations of the Company have been relocated successfully in its new premises at Hoskote Industrial Area, Bangalore during the year. With the commencement of induction of qualified personnel and re-initiation of a few select programs, it is hoped that technology development will be strengthened and lead the Company to greater success

b) The DHA Project

Your Directors are happy to inform you that the Company's 22 litre pilot fermenter is operating well in the new Research Facility under a new team and fine tuning of various processes for the production of fatty acids is underway.

With the publication of its patent by the European Patent Office, work on pushing matters with the USPTO and the Indian Patent Office continues.

The Company hopes to attract partnerships in establishing commercial scale facilities for a number of Fatty Acids, in the days to come.

c) Formation of Special Purpose Vehicles

Your Company has chosen a strategy of incorporating three new wholly owned subsidiaries of ABL Biotechnologies Ltd, in order to facilitate focus on activity and invite investments in the respective business segments. Accordingly three wholly owned subsidiaries were formed on 30th March 2011 as under:

ABL Research Pvt.Ltd, (R & D segment) a wholly owned subsidiary of ABL will now focus on select technologies and developmental objectives, with a view to market requirements and commercialisation objectives

ABL Healthcare Pvt. Ltd (Formulation segment) a wholly owned subsidiary of ABL, will focus on formulation development and manufacture of various types of contract manufacturing businesses. It will seek to successfully commercialise over 450 formulations developed and enhanced them, in the days to come.

ABL Lipids Ltd, (Fatty acids DHA Segment) a wholly owned subsidiary of ABL, will now focus on commercialisation and manufacture of a variety of Fatty Acids and derivatives for the international nutrition and pharmaceutical industry.

Listing

The shares of the Company are listed in the Mumbai and Luxemburg stock exchanges. The shares of the Company are traded in the demat form.

Corporate Governance

The Company continues to follow the code of Corporate Governance during the year under review. A separate report on the same is attached.

Deposits

Your Company has not accepted any deposits from public during the year under review.

Directors

Mr. V M Sankaran Nampoothiri, Director retires by rotation and being eligible offers himself for reappointment.

Auditors

M/s. Pratapkaran Paul & Co., Chartered Accountants, Chennai, Auditors of the Company retire at the ensuing annual general meeting and are eligible for reappointment. A notice has been received under section 224(1B) of the Companies Act, 1956 from them confirming their eligibility for reappointment

Employees

Your Directors place on record their appreciation of the sincere and dedicated services rendered by all the employees during the year under review.

None of the employees have received remuneration in excess of the sum prescribed u/s 217(2A) of the companies Act 1956.

Directors' Responsibility Statement

The Directors confirm that:

- in the preparation of the Annual Accounts, the applicable Accounting Standards have been followed.
- they have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on 31st March, 2011 and of the Profit and Loss of the Company for that period.
- proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- the annual accounts are prepared on a going concern basis

Energy, Technology Absorption & Foreign Exchange

Information in accordance with the provisions of Section 217(1)(e) of the Companies Act, 1956 read with the Companies (Disclosure of Particulars in the Report of the Board of Directors) Rules, 1988 regarding conservation of energy, Technology absorption and Foreign Exchange earnings and outgo are given below:

Conservation of Energy

Energy conservation is not applicable to the biotechnology industry.

Technology Absorption

The technology for microbial metabolites is developed indigenously and hence absorption of foreign technology does not arise.

Foreign Exchange Earnings & Outgo

There were neither any earnings nor any expenditure in foreign exchange during the year.

Research and Development

Research and development facility of the company has been shifted to Hoskote near Bangalore and is fully functional now. Your Company has been continuing its Research and Development activities of extracting bioactive compounds from microbes as well as development of formulations for nutrition and pharmaceuticals.

Acknowledgement

The Board of Directors wishes to place on record its gratitude to Axis Bank Limited and the Department of Science and Technology, Department of Bio-Technology and the other Institutions / Organizations / Agencies who have supported the company during the year.

For and on behalf of the Board of Directors

Date : 05/09/2011
Place: Chennai

K. O. Isaac
Chairman and Managing Director

REPORT ON CORPORATE GOVERNANCE

1. Company's Philosophy

The Company is committed to the principles of good Corporate Governance. The Company is also committed to report financial information transparently and adequately. A judicious and continuous process of empowerment and accountability based on trust, faith and transparency forms the foundation of its growth.

During the financial year 2010-11 five (5) Board Meetings were held on 21.05.2010, 31.07.2010, 7.09.2010, 30.10.2010, 31.1.2011. The Annual General Meeting (AGM) was held on 30th September, 2010.

The composition and membership of the Board and other Board Committees of Directors and attendance of Directors at the Board of Directors meetings held during the financial year 2010-11 and the last AGM held on 30.09.2010 are given in this report.

2. Board of Directors

The Composition and category of Directors as on March 31st, 2011 is as follows:

Name of the Director	Category	Attendance Particulars		Number of other Directorships and Committee Members /Chairmanships		
		Board Meetings	Last AGM	Other Director-Ships	Committee Member-Ships (other than in ABL)	Committee Chairman-Ships (other than in ABL)
K. O. Isaac	Chairman and Managing Director - Executive Director	5	Yes	2	Nil	Nil
G. Subramanian	Non-Executive Independent Director	5	No	Nil	Nil	Nil
Mr. V M Sankaran Nampoothiri	Non-Executive Independent Director	5	Yes	1	Nil	Nil

The Board comprising of two independent directors out of the present strength of three Directors is in conformity with Clause 49 of the Listing Agreement.

3. Board Committees

a) Audit Committee:

The Primary Objective of the Audit Committee of the Company is to monitor and provide effective supervision of the Management's financial reporting process, with a view to ensure accurate, timely and proper disclosures and the transparency, integrity and quality of financial reporting.

The major terms of reference of this committee are as under:

Reviewing the financial statements with the Management before submission of the same to the Board.
 Overseeing of Company's financial reporting process and disclosures of its financial information.
 Reviewing the adequacy of the internal audit function.
 Recommendation for appointment and removal of Statutory Auditors and fixation of audit fees.
 Reviewing the reports furnished by the internal auditors and statutory auditors and ensuring suitable follow up thereon.

During the financial year four Audit Committee meetings were held on 29.04.2010, 30.07.2010, 24.10.2010 and 31.01.2011.

Composition and Attendance

Name of the Directors	No. of Meetings attended
Mr. V M Sankaran Nampoothiri Chairman	4
Dr. G. Subramanian Independent Director	2
Mr. K.O Isaac Managing Director	4

The Company derived immense benefit from the deliberations of the Audit Committee.

b) Remuneration Committee:

The Remuneration Committee comprises of two non-executive Directors:

Name of the Director	Category of Membership
Dr. G. Subramanian	Chairman
Mr. V M Sankaran Nampoothiri	Member

No meeting of the Remuneration Committee was held during the year.

c) Shareholders / Investors' Grievance and Share Transfer Committee:

The Committee oversees the performance of share transfer agents and recommends measures to improve the shareholders'/investors' services. Committee specifically looks into redressal of shareholders' and investors' complaints such as transfer of shares, non-receipt of shares, conversion of shares and to ensure expeditious share transfers.

Meeting and Attendance:

The Shareholders / Investors' Grievance and Share Transfer Committee comprising of following Directors met 4 times during the year 2010-11.

Name of the Director	Meetings attended
Dr. G. Subramanian Chairman	2
Mr. V M Sankaran Nampoothiri Independent Director	4
Mr. K.O. Isaac Managing Director	4

The Managing Director Mr. K.O Isaac is the compliance officer.

Shareholders queries received and replied.

During the Financial Year 2010-11, no complaints were received from shareholders. There are no complaints pending as on the date of this report. There were no share transfers pending registration as on 31st March, 2011.

4. General Body Meetings

The particulars of the Annual General Meetings held during the last three years are as under:

Year	Date and Time	Venue
2009-10	30 th September, 2010 at 9 a.m.	Hotel Mathus, East Coast Road, Thiruvanimiyur, Chennai – 600 041
2008-09	28 th December, 2009 at 9 a.m.	Hotel Mathus, East Coast Road, Thiruvanimiyur, Chennai – 600 041
2007-08	30 th September 2008 at 10 a.m.	Narada Gana Sabha, Mini Hall, Alwarpet, Chennai – 600 018
2006-07	22 nd June 2007 at 10.15 a.m	Narada Gana Sabha, Mini Hall, Alwarpet, Chennai – 600 018

Resolutions

2006 – 07

No special resolution was listed in the agenda. Resolutions under Sections 293(1)(a) and 293 (1) (d) of the Companies Act, 1956 to borrow money and to pledge, mortgage, hypothecate upto a limit not exceeding Rs. 500 Crores

2007 – 08

Resolution for appointment of Mr. K O Isaac as Managing Director of the Company for a period of three years as per the terms approved by the Central Government.

2008 -09

Resolution that pursuant to Section 255 and all other application provisions, if any of the Companies Act, 1956, Mr. V.M. Sankaran Nampoothiri be and is hereby appointed as Director of the Company liable to retire by rotation.

2009-10

To reappoint Dr. G.Subramanian, who retires by rotation during this AGM.

5. Disclosures

The Company has not entered into any transactions of a material nature with the Promoters, the Directors or the Management, their subsidiaries or relatives, etc, that may have potential conflict with the interests of the Company. The necessary disclosures regarding related party transactions are given in the Notes to the Accounts.

6. Means of Communications

The quarterly financial results are published in the English and regional newspapers.